Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial

Treatment regimen an iwCLL and MRD response.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2024-06, Vol.99 (6), p.1192-1195
Hauptverfasser:	Cramer, Paula, Tresckow, Julia, Fink, Anna‐Maria, Robrecht, Sandra, Giza, Adam, Tausch, Eugen, Müller, Lothar, Knauf, Wolfgang, Zingerle, Matthias, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Kreuzer, Karl‐Anton, Kneba, Michael, Wendtner, Clemens‐Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - administration & dosage Bendamustine Hydrochloride - therapeutic use Chronic lymphocytic leukemia Female Humans Immunotherapy Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphatic leukemia Male Middle Aged Monoclonal antibodies Purines - administration & dosage Purines - adverse effects Purines - therapeutic use Quinazolinones - administration & dosage Quinazolinones - adverse effects Quinazolinones - therapeutic use Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!